Physician profile
Daniel Nolan
NPI 1902163025
$1,363.26
in general payments reported to CMS, 2019-2025
10 companies · $94.05 in 2025
The $94.05 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $30.10 · 2022: $335 · 2023: $60.36 · 2024: $254 · 2025: $94.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $370.47 | 2019-2022 | |
| Alcon Vision LLC | $274.43 | 2019-2025 | Luxor, Rocklatan, Simbrinza |
| Aerie Pharmaceuticals, INC. | $220.35 | 2019-2020 | |
| New World Medical,INC. | $202.91 | 2024 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.49 | 2019 | |
| Abbvie INC. | $70.84 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $60.19 | 2022-2023 | Xiidra |
| Tarsus Pharmaceuticals, INC. | $29.10 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $20.99 | 2022 | |
| Amgen INC. | $19.49 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.